Vascular Endothelial Growth Factor Sequestration Enhances In Vivo Cartilage Formation by Medeiros Da Cunha, Carolina M. et al.
 International Journal of 
Molecular Sciences
Article
Vascular Endothelial Growth Factor Sequestration
Enhances In Vivo Cartilage Formation
Carolina M. Medeiros Da Cunha 1, Valeria Perugini 2, Petra Bernegger 1, Matteo Centola 1,†,
Andrea Barbero 1 ID , Anna L. Guildford 2, Matteo Santin 2, Andrea Banfi 1 ID , Ivan Martin 1 ID
and Anna Marsano 1,*
1 Department of Surgery, University Hospital Basel, and Department of Biomedicine, University of Basel,
Hebelstrasse 20, 4031 Basel, Switzerland; carol_medeiros@yahoo.com (C.M.M.D.C.);
petrabernegger@gmail.com (P.B.); mcentola@anikatherapeutics.com (M.C.); andrea.barbero@usb.ch (A.B.);
andrea.banfi@usb.ch (A.B.); Ivan.martin@usb.ch (I.M.)
2 Brighton Studies in Tissue-mimicry and Aided Regeneration, Centre for Regenerative Medicine and Devices,
University of Brighton, Huxley Building Lewes Road, Brighton BN2 4GJ, UK;
v.perugini@brighton.ac.uk (V.P.); anna@etaliauk.com (A.L.G.); M.Santin@brighton.ac.uk (M.S.)
* Correspondence: Anna.Marsano@usb.ch; Tel.: +41-061-265-2979
† Current Address: Anika Therapeutics Srl, Corso Stati Uniti 4/U, 35127 Padova, Italy.
Received: 10 October 2017; Accepted: 15 November 2017; Published: 21 November 2017
Abstract: Autologous chondrocyte transplantation for cartilage repair still has unsatisfactory clinical
outcomes because of inter-donor variability and poor cartilage quality formation. Re-differentiation
of monolayer-expanded human chondrocytes is not easy in the absence of potent morphogens.
The Vascular Endothelial Growth Factor (VEGF) plays a master role in angiogenesis and in negatively
regulating cartilage growth by stimulating vascular invasion and ossification. Therefore, we
hypothesized that its sole microenvironmental blockade by either VEGF sequestration by soluble
VEGF receptor-2 (Flk-1) or by antiangiogenic hyperbranched peptides could improve chondrogenesis
of expanded human nasal chondrocytes (NC) freshly seeded on collagen scaffolds. Chondrogenesis of
several NC donors was assessed either in vitro or ectopically in nude mice. VEGF blockade appeared
not to affect NC in vitro differentiation, whereas it efficiently inhibited blood vessel ingrowth in vivo.
After 8 weeks, in vivo glycosaminoglycan deposition was approximately two-fold higher when
antiangiogenic approaches were used, as compared to the control group. Our data indicates that
the inhibition of VEGF signaling, independently of the specific implementation mode, has profound
effects on in vivo NC chondrogenesis, even in the absence of chondroinductive signals during prior
culture or at the implantation site.
Keywords: chondrogenesis; dendron; soluble VEGF receptor-2; nasal chondrocyte; collagen scaffold
1. Introduction
The treatment of focal articular lesions still remains an unresolved clinical issue, despite the recent
advancement of cell-based repair strategies [1]. Autologous articular chondrocyte-based implantation
techniques have led to significant improvements in the clinical outcomes but cannot guarantee durable,
functionally competent restoration of cartilage [2,3]. High inter-donor variability [4] and loss of
phenotypic specificity during in vitro expansion [5,6] are critical issues which affect the chondrocyte
potential to form stable cartilage in vivo.
Hyaline articular cartilage is avascular in nature and the maintenance of an avascular environment
seems to be crucial for cartilage development and homeostasis [7]. The Vascular Endothelial
Growth Factor (VEGF) is a crucial regulator of angiogenesis [8,9] and skeletal growth [10–12]:
in particular, it mediates vascular invasion of hypertrophic cartilage during endochondral ossification.
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Thus, the blocking of angiogenesis by sequestering microenvironmental VEGF has been considered
as a strategy to support and enhance cartilage repair, possibly in conjunction with cellular therapy.
Kubo et al. [13] genetically modified muscle-derived stem cells to express soluble Flt-1, the extracellular
cleaved form of VEGFR-1, which can act as decoy receptor resulting in angiogenesis blockade.
These cells supported enhanced cartilage repair, but only when combined with a potent morphogen,
namely BMP-4 [13]. Alternatively, the blocking of angiogenesis can be achieved by chondro-supportive
scaffolds functionalized to release humanized VEGF antibodies [14] or with synthetic antiangiogenic
peptides [15] able to form complexes with VEGF, thus preventing its binding to VEGFR-2 [16].
Recently, these linear VEGF blocker peptides with sequence WHLPFKC have been designed in
a hyperbranched formulation able to expose the aptamer sequence at higher density to the surrounding
biological microenvironment and protract the inhibitory effect on endothelial cell proliferation and
sprouting in vitro [17–19]. However, the use of the resulting dendrons to support chondrogenesis has
not yet been tested.
In this study, we aimed at investigating the effects of blocking angiogenesis on the
cartilage-forming capacity of de-differentiated human nasal chondrocytes (NC). NC were chosen
for their high clinical translation potential for articular cartilage repair, due to their safety [20,21],
compatibility with articular cartilage repair [2], ease of harvest, and low donor site morbidity [8,22].
VEGF blockade was achieved by two different methods. The first one relied on NC transduction to
overexpress the highest affinity soluble VEGF receptor, namely sFlk-1, and immediate loading on
a collagen sponge [23], while the other was based on the direct functionalization of the collagen sponge
with synthetic hyperbranched antiangiogenic peptides prior to NC loading. The anti-angiogenic and
chondrogenic capacity of the resulting cellular constructs was assessed following implantation in
a subcutaneous mouse model, which is highly vascularized and not supportive of chondrogenesis,
unless implants have a strong intrinsic chondroinductive capacity [24].
2. Results
2.1. In Vitro Characterization of Engineered Nasal Chondrocytes
Human nasal chondrocytes (NC) were transduced with a retroviral vector expressing a truncated
version of murine CD8a, alone or linked to sFLk-1 in a bicistronic construct. CD8a-only transduced cell
populations (control) and CD8a-sFlk-1-transduced cells were FACS-purified for positive CD8a expression
to eliminate non-transduced cells (Figure 1A). The transduction efficiency for NC was 86.5± 9.2% (n = 3).
The transduction process did not impair the proliferation potential of NC, as the total cell doublings
achieved in 14 days by naïve, control, and sFlk-1 transduced NC were similar (9.5 ± 1.3, 8.8 ± 1.7,
and 9.2 ± 2.0, respectively), consistent with previous findings [25]. ELISA quantification showed that
monolayer-expanded transduced NC released 1.07± 0.41 ng/106 cells/day of sFlk-1.
Human umbilical vein endothelial cells (HUVEC) proliferation and migration assays were
performed in order to assess the activity of sFlk-1 released by transduced NC. Supernatants collected
from monolayer expansion of sFlk-1-expressing NC significantly reduced HUVEC proliferation,
assessed by quantification of the total metabolic activity, induced by concentrations of VEGF up
to 10 ng/mL (Figure 1B).
sFlk-1-releasing NC also hindered the migration of HUVEC under two different concentrations of
VEGF (namely 2.5 and 7.5 ng/mL). On the other hand, the control NC were permissive to the migration
of HUVEC cells (Figure 1C). Taken together, these data show that sFlk-1 secreted by transduced NC is
functionally active to block VEGF effects in vitro.
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Figure 1. In vitro expression of CD8 and bio-activity of the sFlk-1 released by genetically modified 
human nasal chondrocytes. (A) Representative Fluorescence-activated cell sorting (FACS) plot 
shows that nasal chondrocytes (NC) had transduction efficiency above 80% (green-tinted plot) and 
populations of CD8-positive cells were purified after sorting (blue-tinted line). Not stained cells 
were acquired as control (in red). (B) Human umbilical vein endothelial cells (HUVEC) metabolic 
activity assay showing that sFlk-1-containing supernatants efficiently blocks Vascular Endothelial 
Growth Factor (VEGF). CD8-expressing NC supernatants were used as control (2 donors, n = 4). (C) 
HUVEC migration assay after 12 h showing that sFlk-1-expressing NC hampered HUVEC 
migration by blocking different gradients of VEGF, whereas CD8-only expressing NC allowed 
HUVEC migration. * p < 0.01. 
2.2. In Vitro Chondrogenesis 
Naïve (Naïve), mock-sorted (Naïve_S), CD8a- (CD8, transduction control), and 
sFlk-1-CD8a-expressing (sFlk-1) cell populations were used to investigate the effect of the VEGF 
blockade and the transduction and sorting processes on the in vitro NC chondrocytic 
re-differentiation capacity (n = 3). Since hypoxic culture conditions were shown to influence in vitro 
cell chondrogenic capacity, the pellet culture was performed at either 2% or 20% of oxygen tension. 
Cartilaginous extracellular matrix was formed in naïve, sorted naïve (naïve_S), and CD8 pellets, 
whereas lower deposition occurred in sFlk-1 pellets in 20% oxygen, as shown by the Safranin-O 
staining in 20% oxygen (Figure 2A). There was not a statistical significant difference between the 
glycosaminoglycan (GAG) amounts deposited by the naïve sorted and CD8-expressing NC, at either 
oxygen tension (Figure 2B). Nevertheless, a negative trend was present for the GAG/DNA ratio for 
Naïve-S at 2% of oxygen and for the sFlk-1 expressing NC at 20% of oxygen tension. Since the sorting 
and transduction process alone appeared not to affect the chondrogenic potential in vitro of NC, 
naïve cells were used as control group for the experiments in vivo. Mouse sFlk-1 was quantified by 
ELISA in the supernatant of NC after pellet culture. sFlk-1-transduced NC pellets expressed 
approximately 30 ng/pellet/day of sFlk-1 under 20% and 2% O2 (Figure 2C). Thus, sFlk-1 release was 
not affected by the different oxygen tensions used for pellet culture. As expected, murine sFlk-1 
expression in naïve and CD8- transduced cells remained undetected. 
Figure 1. In vitro expression of CD8 and bio-activity of the sFlk-1 released by genetically modified
human nasal chondrocytes. (A) Representative Fluorescence-activated cell sorting (FACS) plot shows
that nasal chondrocytes (NC) had transduction efficiency above 80% (green-tinted plot) and populations
of CD8-positive cells were purified after sorting (blue-tinted line). Not stained cells were acquired
as control (in red). (B) Human umbilical vein endothelial cells (HUVEC) metabolic activity assay
showing that sFlk-1-containing supernatants efficiently blocks Vascular Endothelial Growth Factor
(VEGF). CD8-expressing NC supernatants were used as control (2 donors, n = 4). (C) HUVEC migration
assay after 12 h showing that sFlk-1-expressing NC hampered HUVEC migration by blocking different
gradients of VEGF, whereas CD8-only expressing NC allowed HUVEC migration. * p < 0.01.
2.2. In Vitro Chondrogenesis
Naïve (Naïve), mock-sorted (Naïve_S), CD8a- (CD8, transduction control), and
sFlk-1-CD8a-expressing (sFlk-1) cell populations were used to investigate the effect of the
VEGF blockade and the transduction and sorting processes on the in vitro NC chondrocytic
re-differentiation capacity (n = 3). Since hypoxic culture conditions were shown to influence in vitro
cell chondrogenic capacity, the pellet culture was performed at either 2% or 20% of oxygen tension.
Cartilaginous extracellular matrix was formed in naïve, sorted naïve (naïve_S), and CD8 pellets,
whereas lower deposition occurred in sFlk-1 pellets in 20% oxygen, as shown by the Safranin-O
staining in 20% oxygen (Figure 2A). There was not a statistical significant difference between the
glycosaminoglycan (GAG) amounts deposited by the naïve sorted and CD8-expressing NC, at either
oxygen tension (Figure 2B). Nevertheless, a negative trend was present for the GAG/DNA ratio for
Naïve-S at 2% of oxygen and for the sFlk-1 expressing NC at 20% of oxygen tension. Since the sorting
and transduction process alone appeared not to affect the chondrogenic potential in vitro of NC, naïve
cells were used as control group for the experiments in vivo. Mouse sFlk-1 was quantified by ELISA
in the supernatant of NC after pellet culture. sFlk-1-transduced NC pellets expressed approximately
30 ng/pellet/day of sFlk-1 under 20% and 2% O2 (Figure 2C). Thus, sFlk-1 release was not affected by
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the different oxygen tensions used for pellet culture. As expected, murine sFlk-1 expression in naïve
and CD8- transduced cells remained undetected.
Int. J. Mol. Sci. 2017, 18, 2478 4 of 14 
 
 
Figure 2. In vitro chondrogenesis of nasal chondrocytes. (A) Representative Safranin-O staining 
images of NC cultured in pellets at 20% of oxygen tension. Naïve, naïve mock-sorted (Naïve sorted), 
CD8 (control), and sFlk-1-releasing NC were cultured in vitro in pellets and analyzed for their 
chondrogenic potential. (B) Glycosaminoglycan (GAG) content of pellets generated by NC cultured 
at either 2% or 20% of oxygen tension (2 donors, n = 9). (C) Amount of mouse sFlk-1 released by 
sFlk-1-expressing NC-based pellets cultured at different oxygen tensions (2 donors, n = 4). No 
statistical significant difference has been found. 
2.3. In Vivo Blocking of Angiogenesis 
We first investigated whether sFlk-1 and the dendronized peptide of WHLPFKC were capable 
of blocking VEGF in vivo. Vessel ingrowth within the implant was investigated 8 weeks after ectopic 
subcutaneous implantation of cell-loaded constructs in nude mice. In both sFlk-1-expressing and 
dendron-based constructs, CD31-positive blood vessels could be observed only in the host tissue 
surrounding the constructs, proving their ability to efficiently block angiogenesis within the implant 
area (Figure 3A). Only in the control (naïve NC) samples could CD31-positive vessels be observed 
both at the edge and within the center of the implants, indicating vascular invasion (Figure 3A,B). 
Mouse-origin macrophages, positive for F4/80, were highly present within the center and periphery 
of control samples, whereas in the VEGF sequestrating groups, their infiltration was very low and 
limited to the edges of the implants (Figure 3A). At the edge of the constructs treated with dendrons 
or loaded with sFlk-1 expressing NC, we noticed a reduced number of vessel density as compared to 
the control, showing the potential to block host vasculature ingrowth also at the periphery of the 
implant. Taken together, these data show that both sFlk-1 and the dendronized WHLPFKC peptide 
were effective in blocking in vivo VEGF activity on both vessel invasion and macrophage 
recruitment. 
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Figure 3. In vivo blocking of angiogenesis. (A) Representative immunofluorescence pictures of 
control (naïve NC), sFlk-1, and dendron-based constructs stained either in red for PECAM (CD31), 
an endothelial marker, (first raw, scale bar = 100 µm) or in green for F4/80, a macrophage marker 
(second raw, scale bar = 50 µm). Cell nuclei were stained in blue with DAPI (A). White arrows 
indicate the vascular structures, whereas white dotted lines mark the boundary between the implant 
and the surrounding host tissue. Asterisks indicate the implant area. (B) Quantification of the vessel 
length density in µm/µm2 at the center or edge of the implant area of naïve, sFlk-1, and 
dendron-based constructs (1 donor, n = 4). * p < 0.01. 
2.4. In Vivo Chondrogenesis 
Implanted tissues were also assessed for their in vivo chondrogenic potential. In vivo 
chondrogenesis was assessed after direct implantation of freshly seeded NC on Ultrafoam® 
scaffolds. Since the cell transduction and sorting did not influence the chondrogenic capacity of 
nasal chondrocytes, we used only naïve cells as controls. Constructs engineered by CD8-expressing 
NC indeed displayed a strong positive staining for GAG and type II collagen, and resulted to be 
almost negative for the type X collagen also following 8 weeks in vivo (Supplementary Materials 
Figure S1). 
Cartilaginous extracellular matrix, detected by positive staining for Safranin-O, was formed by 
both control (naïve) and sFlk-1-expressing cells already after 4 weeks in vivo. Constructs generated 
with sFlk-1 cells contained larger Safranin-O areas (Figure 4A) as comparted to those generated by 
controls cells and accumulated larger amounts of GAG (Figure 4C). After 8 weeks in vivo, similarly 
to control samples, sFlk-1 cartilage-like constructs were positive for type II (hyaline cartilage-specific 
marker) and negative for type X (hypertrophic marker) collagens in the center of the implant where 
cartilage was formed, indicating a stable phenotype (Figure 4B). 
Figure 3. In vivo blocking of angiogenesis. (A) Representative immunofluorescence pictures of
control (naïve NC), sFlk-1, and dendron-based constructs stained either in red for PECAM (CD31),
an endothelial marker, (first raw, scale bar = 100 µm) or in green for F4/80, a macrophage marker
(second raw, scale bar = 50 µm). Cell nuclei were stained in blue with DAPI (A). White arrows indicate
the vascular structures, whereas hite dotted lines mark the boundary between the implant and the
surrounding host tissue. Asterisks indicate the implant area. (B) Quantification of the vessel length
density in µm/µm2 at the center or edge of the implant area of naïve, sFlk-1, and dendron-based
constructs (1 donor, n = 4). * p < 0.01.
2.4. In Vivo Chondrogenesis
Implanted tissues were also assessed for their in vivo chondrogenic potential. In vivo
chondrogenesis was assessed after direct implantation of freshly seeded NC on Ultrafoam® scaffolds.
Since the cell transduction and sorting did not influence the chondrogenic capacity of nasal
chondrocytes, we used only naïve cells as controls. Constructs engineered by CD8-expressing NC
indeed displayed a strong positive staining for GAG and type II collagen, and resulted to be almost
negative for the type X collagen also following 8 weeks in vivo (Supplementary Materials Figure S1).
Cartilaginous extracellular matrix, detected by positive staining for Safranin-O, was formed by
both control (naïve) and sFlk-1-expressing cells already after 4 weeks in vivo. Constructs generated
with sFlk-1 cells contained larger Safranin-O areas (Figure 4A) as comparted to those generated by
controls cells and accumulated larger amounts of GAG (Figure 4C). After 8 weeks in vivo, similarly
to control samples, sFlk-1 cartilage-like constructs were positive for type II (hyaline cartilage-specific
marker) and negative for type X (hypertrophic marker) collagens in the center of the implant where
cartilage was formed, indicating a stable phenotype (Figure 4B).
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Figure 4. In vivo chondrogenesis of nasal chondrocytes—cell-based gene therapy approach. (A) 
Safranin-O staining for naïve (control) and sFlk-1-releasing NC after 8 weeks in vivo. (B) Types II 
and X collagen stainings for naïve and sFlk-1 NC at 8 weeks in vivo. (C) Total amount of GAG 
deposited in vivo at 4 and 8 weeks by naïve and sFlk-1 expressing NC (2 donors, n = 8). * p < 0.01. 
Scale bars = 50 µm. 
In vivo chondrogenesis of NC was also investigated with dendron-based constructs. The 
enhanced cartilage forming capacity of the dendron-based construct was evident after 8 weeks in 
vivo. Safranin-O staining was intense for both control and dendron-based constructs, but the latter 
displayed a more uniform spatial distribution of GAG (Figure 5A). Biochemical analyses of GAG 
deposition confirmed the finding that the anti-angiogenic dendronized peptide significantly 
enhanced the in vivo cartilage forming capacity of NC at 8 weeks (Figure 5B). Type II collagen was 
immunodetected in both groups. In the dendron-based constructs, the central part was mainly 
cartilaginous and expressed low type X collagen. At the edges in contact with the host connective 
tissue instead type X was highly expressed (Figure 5A). 
Figure 4. In vivo chondrogenesis of nasal chondrocytes—cell-based gene therapy approach.
(A) Safranin-O staining for naïve (control) and sFlk-1-releasing NC after 8 weeks in vivo. (B) Types
II and X collagen stainings for naïve and sFlk-1 NC at 8 weeks in vivo. (C) Total amount of GAG
deposited in vivo at 4 and 8 weeks by naïve and sFlk-1 expressing NC (2 donors, n = 8). * p < 0.01.
Scale bars = 50 µm.
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Figure 5. In vivo chondrogenesis of nasal chondrocytes-dendron-functionalized approach. (A) 
Safranin-O, types II and X collagen staining for control (naïve NC) and dendron-based constructs at 
8 weeks in vivo. Dotted white line indicates the cartilaginous part of the dendron based implants. 
Scale bar = 50 µm. (B) Total GAG production in vivo at 4 and 8 weeks by control (naïve NC) and 
dendron-based constructs (1 donor, n = 5). * p < 0.01.  
3. Discussion 
In this study, we demonstrated that two unrelated methods to block angiogenesis have a great 
impact on the in vivo chondrogenic potential of non-pre-committed NC by enhancing 
glycosaminoglycan (GAG) deposition as compared to controls. VEGF blockade in the surroundings 
of the implanted human NC, in order to inhibit blood vessel ingrowth within the implant area, 
might also reduce the risk of resorption of non-mature constructs [14] and supports chondrogenesis. 
Anti-angiogenic approaches showed improvement in cartilage repair by either applying an 
adeno-associated virus carrying the chondromodulin-1 gene [26] or by injecting mouse 
muscle-derived stem cells genetically modified to express the soluble version of Flt-1 combined with 
Figure 5. In vivo chondrogenesis of nasal chondrocytes-dendron-functionalized approach.
(A) Safranin-O, types II and X collagen staining for control (naïve NC) and dendron-based constructs
at 8 weeks in vivo. Dotted white line indicates the cartilaginous part of the dendron based implants.
Scale bar = 50 µm. (B) Total GAG production in vivo at 4 and 8 weeks by control (naïve NC) and
dendron-based constructs (1 donor, n = 5). * p < 0.01.
3. Discussion
In this study, we demonstrated that two unrelated methods to block angiogenesis have
a great impact on the in vivo chondrogenic potential of non-pre-committed NC by enhancing
glycosaminoglycan (GAG) deposition as compared to controls. VEGF blockade in the surroundings
of the implanted human NC, in order to inhibit blood vessel ingrowth within the implant
area, might also reduce the risk of resorption of non-mature constructs [14] and supports
chondrogenesis. Anti-angiogenic approaches showed improvement in cartilage repair by either
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applying an adeno-associated virus carrying the chondromodulin-1 gene [26] or by injecting mouse
muscle-derived stem cells genetically modified to express the soluble version of Flt-1 combined
with morphogenic factors [13] in knee cartilage lesions. These previous studies differ from the
present investigation because of both the in vivo animal model adopted and the target cell types
used: animal-origin native articular versus human de-differentiated nasal chondrocytes. While Kubo’s
study indeed aimed at investigating the effects on cartilage repair of several growth factors, released
by the genetically modified stem cells (which served mainly as a delivery system), Ref.[13] the
goal of the present study was to generate a protected and chondro-permissive environment to
allow sFlk-1-expressing NC re-differentiation. However, as in the previously mentioned studies,
the enhanced chondrogenesis observed by adopting antiangiogenic strategies appears to be associated
only with paracrine signaling to the host environment, since the in vitro chondrogenic potential was not
directly affected by VEGF blockade or other antiangiogenic factors, such as endostatin [27]. Since the
effects of VEGF blockade on chondrogenesis take place when host vascular invasion is prevented
from happening in vivo [23], differences in NC differentiation potential were not observed in vitro.
Paracrine VEGF signaling is crucial for angiogenesis to take place, including effects on EC proliferation,
survival, migration, and endothelial differentiation [28]. Since one of the immediate consequences
of inhibition of angiogenesis is the generation of a hypoxic environment, which is a key regulator of
chondrogenesis during limb development [29], this study also investigated the in vitro effect of VEGF
blockade at low oxygen tension. Based on the in vitro results of this investigation, it can be concluded
that the mechanisms of chondrogenesis in vivo are controlled by factors beyond the combined effect of
hypoxia and morphogen gradient availability. The lack of nutrients is also a direct consequence of the
absence of blood vessel supply; low glucose culture has been shown to regulate the oxygen tension
within engineered tissues [30] and the chondrogenesis capacity of chondrocytes [31]. Hence, glucose
availability may be directly involved in NC chondrogenesis. The lack of vessels could prevent the
infiltration of immune cells, such as macrophages, which can induce host reaction against the implant
and bring about its premature resorption. Luo et al., have demonstrated that a milder inflammatory
response by the host tissue occurs when a 2-week in vitro pre-cultured chondrocyte-based construct is
implanted in vivo compared to a “no pre-culture group” [32]. Other studies have also reported that
in vitro preconditioning can mitigate the post-implantation inflammatory reaction and how cartilage
maturation is correlated with a different inflammatory chemokine production [33]. The present findings
clearly highlight the different levels of macrophage invasion within the control groups, whereas the
antiangiogenic groups (sFlk-1 and dendron-associated implants) displayed a diminished macrophage
invasion, improving the cartilage quality and hampering its resorption through inflammatory
reactions [14].
Thus, vessel ingrowth and the subsequent inflammatory reaction that take place in immature
cartilaginous engineering constructs appear highly detrimental for cartilage formation. A clear control
over host blood vessel invasion and inflammatory responses is likely to avoid tissue resorption at
a later stage of the treatment [14]. The here presented results suggest that the blockage of vessel
ingrowth also decreases the infiltration of inflammatory cells allowing the formation of stable cartilage
up to 8 weeks in vivo without the need of a pre-culture period, being therefore highly attractive
for clinical applications. However, in view of translating this concept into clinical approaches,
further investigations are needed. In the present study, the effects of sFlk-1 and the WHLPFKC
peptide on cartilage formation by NC were investigated in an ectopic environment, which is highly
vascularized and permissive but not inductive to chondrogenesis [24], thus providing a reliable
proof of principle of the clinical potential of these antiangiogenic treatments. However, further
investigations in an orthotopic environment, where various physiological stimuli (e.g., mechanical
loading and exposure of the NC to the cartilaginous milieu) are taken into account, are necessary to
prove the cartilage long-term stability. Although both approaches here investigated efficiently blocked
angiogenesis and supported chondrogenesis up to 8 weeks in vivo, they differ in the time of efficacy
and in their clinical translational potential. Cell-based gene therapy indeed guarantees a sustained
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release of proteins, whereas the scaffold functionalized with the antiangiogenic peptide might be
limited to the dendron reservoir capacity offered by the implanted scaffold. The time during which
the antiangiogenic effect needs to be maintained in order to induce chondrogenesis still needs to be
elucidated. However, the above proposed study in an orthotopic model will be highly relevant to
fully assess the clinical potential of each approach. If a sustained antiangiogenic effect was found to
be essential, retroviral vectors might be substituted by lentiviruses, which have become the vector
of choice in clinical applications requiring indefinite expression of the therapeutic gene due to their
significantly better safety profile [34].
4. Materials and Methods
4.1. Cell Isolation and Transduction
Human nasal septal cartilage biopsies were harvested from two donors during plastic surgical
procedures in accordance to the local ethical committee and following informed consent. The nasal
cartilage was digested with a 0.15% type II collagenase solution (1 mL/100 mg of tissue, Worthington
Biochemical Corporation, Lakewood, NJ, USA) for 22 h at 37 ◦C. Nasal chondrocytes (NC) were
cultured at 37 ◦C and 5% CO2 at a density of 5000 cells/cm2 in high glucose Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% FBS, 1% Hepes (Gibco), 1% penicillin-streptomycin
solution (Gibco, Zug, Switzerland), 1% sodium pyruvate (Gibco), 0.29 mg/mL L-glutamate (complete
medium, CM) and with 5 ng/mL fibroblast growth factor-2 (FGF-2), and 1 ng/mL of transforming
growth factor β1 (TGFβ1) (R&D Systems, Abingdon, UK) [2].
The NC were transduced with retroviral vectors carrying the gene for mouse sFlk-1 linked
through an internal ribosomal entry site (IRES) to a non-functional truncated version of mouse
CD8a, as a convenient syngenic cell surface marker to allow Fluorescence-Activated Cell Sorting
(FACS) [35]. For control purposes, NC transduced only with the truncated murine CD8a and either
mock-sorted or naïve cells were used. Cells were transduced at high efficiency according to a published
protocol [25,36]. Briefly, the NC were incubated with retroviral vector supernatants supplemented
with 8 µg/mL polybrene (Sigma-Aldrich, Buchs, Switzerland) for 5 min at 37 ◦C and then centrifuged
at 1100× g for 30 min at room temperature (RT), followed by fresh medium replacement. Cells were
then expanded for two additional passages.
4.2. In Vitro 3D Pellet Culture
3D NC pellets were formed as previously described [37] and cultured in a serum-free medium
(SFM), which consists of DMEM, supplemented with 1% Hepes, 1% penicillin–streptomycin solution,
1% sodium pyruvate, 1% Insulin–transferrin–sodium selenite (ITS + 1, Sigma-Aldrich), 1% human
serum albumin (HSA 100×, Invitrogen, Basel, Switzerland), 0.1 mM ascorbic acid 2-phosphate
(Invitrogen), and dexamethasone 10−7 M (Invitrogen), then supplemented with 10 ng/mL of TGFβ-1.
The pellets (made of not transduced (naïve), mock-sorted (naïve sorted), or cells transduced for
expressing truncated CD8 alone (CD8) or in combination with sFlk-1) were cultured for 2 weeks at
2% or 20% oxygen tension. The supernatants of the pellet culture were collected and used for human
sFlk-1 quantification (described below).
4.3. Synthesis and Characterization of Peptide VEGF Blockers
FFG3K (WHLPFKC)16 was assembled on Tenta Gel S-NH2 resin using an acid labile Rink
amide linker (Iris Biotech GmbH, Marktredwitz, Germany) by a modified microwave based solid
phase peptide synthesiser (Biotage, Ystrad Mynach, Hengoed, UK) and then isolated using 94%
v/v TFA (Fisher Scientific, Loughborough, UK), 2.5% v/v deionised H2O, 1% v/v 1,2-ethandithiol
(Sigma Aldrich Co., Ltd., Irvine, Ayrshire, UK), and 2.5% v/v trisopropyl silane (TIPS) (Sigma Aldrich
Co., Ltd., Irvine, Ayrshire, UK). The dendron was characterized by analytical HPLC (Waters TM
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717 plus Autosampler, Elstree, Herts, UK), mass spectrometry (MS) (Bruker microTOF, Coventry, UK),
and gravimetric analysis as previously reported [17].
4.4. 3D Construct Preparation
A commercially available type I collagen-based sponge (UltrafoamTM, Bard Medica S.A., Zurich,
Switzerland) of 3 mm thickness was punched into 6 mm diameter disks and then seeded at the density
of 1.7 × 106 cells per scaffold. For the cell-based gene approach, NC transduced to express sFlk-1
linked to CD8a were used. Cells expressing CD8a alone and naïve cells served as control.
Alternatively, for the dendron-functionalized approach, NC were loaded in the presence of
WHLPFKC at a concentration of 1.62 nM, previously reported to produce an anti-angiogenic effect
in vitro [17,18]. All the constructs were incubated with CM before for 24 h prior implantation.
Naïve NC-based constructs without the addition of WHLPFKC were used as control group.
4.5. In Vivo Ectopic Implantation
Cell-based constructs were implanted ectopically (in subcutaneous pockets) in nude mice (CD-1
nude/nude, Charles River). The mice were sacrificed with CO2 at 4 and 8 weeks after the implantation.
Animals were treated in agreement with Swiss legislation and according to a protocol approved by
the Veterinary Office of Canton Basel-Stadt (permission number: 1797, 1 January 2016). All constructs
were implanted in vivo 24 h after the cell seeding.
4.6. Flow Cytometry
The percentage of population positive for CD8a in the sFlk-1-releasing NC and control NC
was assessed by staining with a fluorescein isothiocyanate-conjugated anti-mouse CD8a antibody
(clone 53-6.7; BD Biosciences, Allschwil, Switzerland) using 0.8 µg of antibody/106 cells in 200 µL
of PBS with 5% bovine serum albumin. [35] Data were acquired with a FACSCalibur flow cytometer
(BD Biosciences, Allschwil, Switzerland) and analyzed using FlowJo software (Tree Star, software
version 10, Ashland, OR, USA).
4.7. Quantification of Murine sFlk-1
Supernatants were collected from monolayer expanded NC or pellets after 4 h or two days of
culture, respectively, and were used for murine sFlk-1 quantification using an ELISA (enzyme-linked
immunosorbent assay) Quantikine immunoassay kit (R&D Systems, Abingdon, UK). Data were
presented as quantity in ng per pellet normalized to the time of incubation.
4.8. Biochemistry
Engineered constructs were digested with protease K for 15 h at 56 ◦C [38]. The glycosaminoglycan
(GAG) and DNA contents were measured spectrophotometrically using dimethylmethylene blue [39]
and the CyQUANT Kit (Molecular Probes, Eugene, OR, USA), respectively. GAG contents were
normalized to the amount of DNA for the in vitro experiments. In the in vivo studies GAG amount
was instead presented as total amount per construct.
4.9. HUVEC Proliferation Assay
Human umbilical vein endothelial cells (HUVEC) were cultured in 96-well plates overnight
in growth medium (GM), consisting of M199 supplemented with 20% fetal bovine serum (FBS),
100 mg/mL endothelial cells growth supplement, 50 IU/mL heparin, 100 IU/mL penicillin,
and 100 mg/mL streptomycin, at a density of 5000 cells/well. The next day, GM was
replaced with assay medium (AM), consisting of M199 with 5% FBS, 10 IU/mL heparin, and
1% penicillin/streptomycin, supplemented with recombinant human VEGF (R&D Systems) at
different concentrations between 0 and 50 ng/mL, and mixed with the supernatant derived from
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either control or sFlk-1 expressing NC. [14] HUVEC proliferation was then assessed by using
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]
(Promega, Dübendorf, Switzerland). The HUVEC were incubated with MTS for 2 h at 37 ◦C and the
measurement of the absorbance of the formazan was carried out at 490 nm.
4.10. HUVEC Migration Assay
HUVEC encapsulation, along with either sFlk-1-expressing or CD8-only expressing NC, was
performed by using a synthetic matrix metalloproteinase (MMP)-degradable extracellular matrix
(ECM) functionalized with RGD peptides to promote degradation and cell adhesion and migration,
respectively (kindly provided by QGel S.A., Lausanne, Switzerland). The HUVEC were first labelled
with syto®13 in green and then seeded at a density of 13 × 104 cells/well on collagen-coated culture
plates. After HUVEC adhesion and proliferation overnight in GM, 100 µL of QGel® with RGD was
polymerized, followed by 100 µL of QGel® without RGD, and 100 µL of sFlk-1-expressing or naïve NC
embedded in QGel® with RGD. The next day, the growth medium was replaced by AM supplemented
either by 0, 2.5, or 7.5 ng/mL of human recombinant VEGF. HUVEC migration was monitored with
time laps for 12 h, using Zeiss LSM 710 confocal microscope. Representative images of the culture
wells following 12 h were taken to show whether the HUVEC migrated.
4.11. Histology
Explanted tissues were fixed with 4% formaldehyde and embedded in paraffin. Sections (5 µm
thick) were stained for Safranin-O and for immunohistochemistry for types II and X collagen.
The primary antibodies used were mouse anti-collagen II (MP Biomedicals, clone II-4C11), and
mouse anti-collagen X (Abcam, Cambridge, UK). As a secondary antibody, goat anti-mouse IgG/Biotin
(Dako, Basel, Switzerland) was used.
Explants dedicated to immunofluorescence analysis were fixed with 1% paraformaldehyde
(Sigma-Aldrich, Buchs, Switzerland) in PBS, then incubated in 10% w/v sucrose (Sigma-Aldrich,
Buchs, Switzerland) and, finally, embedded in OCT compound (Sakura Finetek) frozen in freezing
isopentane (Sigma-Aldrich, Buchs, Switzerland). Immunofluorescence staining was performed
on the 10 µm-thick sections with the following primary antibodies and dilutions: rat anti-mouse
F4/80 antibody (Caltag, RM2900, 1:200) or rat anti-mouse PECAM-1 (CD31, BD 553370, 1:100).
Fluorochrome-conjugated secondary antibodies were used at 1:200 (Invitrogen, Basel, Switzerland).
For immunohistochemistry staining, the intensity and the nonspecific binding of the secondary
antibody were checked by performing negative controls, consisting in the staining without the use of
the primary antibodies.
4.12. Vessel Quantification
The amount of vessels was quantified tracing CD31-positive vessels by using CellSens software
(Olympus). Briefly, three representative fluorescence images were acquired from the center and the
periphery of each construct (n = 3 samples/group) (BX63 microscope, Olympus). The vessel length
density (VLD) was determined by dividing the total traced length of vessels identified in the fields by
the area of the analysed images.
4.13. Statistical Analysis
The data were analysed with the statistical software Prism 5.0 (GraphPad Software Inc., La Jolla,
CA, USA) using one-way analysis of variance (ANOVA) with Bonferroni correction (p < 0.05). Data are
presented as mean ± standard deviation (SD).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/11/2478/s1.
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